| PHUSE US |
2026 |
Accelerating Study Insights: Agile Data Visualisation Using R-Shiny |
Lin Yuan,
Heather Howell |
source
presentation source |
6 |
| PHUSE US |
2026 |
Electronic Submission of Population PK Analysis Files ... What's Your Modus Operandi? |
Luai R. Alzoubi |
source
presentation source |
13 |
| PHUSE EU |
2025 |
But Wait, There's More: When RECIST 1.1 Is Not Enough |
Anny Yamileth Olivares Mundo |
source
poster source |
8 |
| PharmaSUG |
2025 |
Integrated R scripts to Power BI |
Jun Yang |
source |
6 |
| PharmaSUG |
2025 |
Roadmap to Efficacy Analysis for Early Phase Oncology studies |
Dhruv Bansal,
Christiana Hawn,
Chris Kelly |
source |
23 |
| PharmaSUG |
2025 |
Visualizing oncology data through 3D bar charts in R and Python |
Girish Kankipati,
Venkatesulu Salla |
source |
18 |
| PHUSE US |
2025 |
Optimizing Development and Regulatory Submission of eSUB Package for Exposure-Response and PK/PD Analysis |
Saumilkumar Tripathi,
Ephicacy Lifescience |
source
presentation source |
10 |
| MWSUG |
2024 |
Harnessing the Power of PROC CONTENTS and SELECT INTO: SEPARATED BY [presentation] |
Yanfang Pang |
source |
17 |
| WUSS |
2024 |
Automation of Submission of Programs in Analysis Data Reviewer's Guide for FDA and PMDA Submissions |
Junying Zhang |
source |
14 |
| PharmaSUG |
2024 |
Oncology ADaM Datasets Creation Using R Programming: A Comprehensive Approach |
Ishwar Chouhan |
source |
29 |
| PHUSE US |
2024 |
An End User's Perspective of Clinical Dosing Data Used for Population PK/PD Analysis with Non-Linear Mixed Effects Modelling |
Rebecca Humphrey,
Mitali Gaurav |
source
poster source |
2 |
| PharmaSUG |
2023 |
Admiralonco - The Cross-Company R Package for Oncology Admirers |
Neharika Sharma,
Matthew Marino |
source |
25 |
| PharmaSUG |
2023 |
Leverage and Enhance CDISC TAUGs to Build More Traceability for and Streamline Development of Efficacy ADaM in Oncology Studies |
Xiangchen (Bob) Cui |
source |
29 |
| PHUSE EU |
2022 |
The Secret to Getting Your Dream Job Offer [presentation] |
Tom Oades |
source
video |
13 |
| PHUSE EU |
2022 |
Tumour Assessment Evaluation Using MS Azure and Power BI [presentation] |
Robert Adams,
Clara Beck |
source
video |
22 |
| SESUG |
2022 |
A Two-Staged Local Regression Based Binning Method for Weight of Evidence Transformation in Credit Scoring Models |
Hui Wang,
Shirong Huang,
Emma Zhou,
Erin Martin |
source |
30 |
| PharmaSUG |
2022 |
Derivation of Efficacy Endpoints by iRECIST Criteria: A Practical Approach |
Ilya Krivelevich,
Lei Gao,
Richard Kennan |
source |
9 |
| PHUSE EU |
2021 |
An overview of regression approaches for the competing risks data |
Oksana Mykhailova,
Julia Ditkovska |
source
video
presentation source |
6 |
| PHUSE EU |
2021 |
How Has the Immunotherapy Era Changed Response Criteria? [presentation] |
Anna Amosova |
source
video |
30 |
| PHUSE EU |
2021 |
Preparing PK/PD ADaM Datasets and eCRT Data Package for FDA Submission |
Junying Zhang |
source
video
presentation source |
11 |
| PHUSE US |
2021 |
Using Real-world Data in Supporting Health Authority Submission [presentation] |
Ruoying Fang,
Shuang Zhang |
source
video |
26 |
| SGF |
2020 |
Risk Modeling on the Fast-Track: Pythonistas (and Others) Harness the Power of the SAS Risk Engine |
Dave Stonehouse |
source |
9 |
| PharmaSUG |
2020 |
Butterfly Plot for Comparing Two Treatment Responses |
Raghava Pamulapati |
source |
13 |
| PharmaSUG |
2020 |
CDISC-compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials |
Kuldeep Sen,
Sumida Urval,
Yang Wang |
source |
11 |
| PharmaSUG |
2020 |
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies |
Xiangchen (Bob) Cui,
Sri Pavan Vemuri |
source |
24 |
| PHUSE EU |
2019 |
Programming in the World of PK: Guidance for the Beginner |
Paige Lewis |
source
poster source |
7 |
| SGF |
2019 |
Building a Portfolio To Have Limited Maximum Loss with SAS Model Implementation Platform |
João Pires da Cruz,
Carla Tempera,
Manuel Fortes |
source |
12 |
| SGF |
2019 |
Generating Synthetic Instruments for Stress Testing: Machine Learning and Econometrics in SAS Viya |
Rocco Cannizzaro,
Christian Macaro |
source |
8 |
| SGF |
2019 |
Increasing Operational Efficiency by Using SAS in an Automated Process for Credit Scoring Models |
Roberta Pimenta Moreira,
Leonardo de Lima Aguirre,
Alfredo Luiz Venzel de Oliveira |
source |
7 |
| PHUSE US |
2019 |
Efficacy Endpoint Visualization of Investigational Products for Cancer Patients Using R Shiny |
Beverly Martinez,
Mukul K Mittal |
source
presentation source |
12 |
| PHUSE EU |
2018 |
Step-by-step Guide to Efficacy Analysis in Solid Tumors Oncology Clinical Trials |
Anastasiia Tiurdo |
source
presentation source |
11 |
| PHUSE US |
2018 |
Secure Data Office: An Independent Team that Can Come to the Rescue in Blinded Trials |
Annelies Van Zeveren,
Yana Hoorne |
source
presentation source |
9 |
| PHUSE US |
2018 |
Split-Coalesce Tumor Data Handling Woes and Safety-Efficacy Dilemma |
Idya Muthukumar |
source
presentation source |
11 |
| PharmaSUG |
2018 |
How PK and PD analyses drive dataset designs |
David Radtke,
Brian A. Moser |
source |
7 |
| PharmaSUG |
2018 |
Leveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies |
Kelci J. Miclaus,
Lili Li |
source |
12 |
| PHUSE EU |
2017 |
Implementation of CDISC ADaM and Pharmacodynamics |
Françoise Frérart,
Joanna Magielse |
source
presentation source |
5 |
| PHUSE EU |
2017 |
The Secure Data Office Concept |
Annemie Van Dijck |
source
presentation source |
9 |
| PharmaSUG |
2017 |
Population PK/PD Analysis - SAS with R and NONMEM Make Customization Easy |
Sharmeen Reza |
source |
11 |
| PharmaSUG |
2017 |
Programming LYRIC Response in Immunomodulatory Therapy Trials |
Yang Wang |
source |
5 |
| PharmaSUG |
2017 |
Where Is the Link Broken - Another Look at SDTM Oncology Tumor Packages |
Hong Wang,
Ke Xiao |
source |
12 |
| SGF |
2017 |
Modeling Best Practices: An IFRS 9 Case Study |
Peter Baquero,
Ling Xiang |
source |
8 |
| PharmaSUG |
2016 |
Data Visualization for Quality Control in NONMEM Data set |
Linghui Zhang |
source |
9 |
| SGF |
2016 |
Credit Card Interest and Transactional Income Prediction with an Account-Level Transition Panel Data Model Using SAS/STAT and SAS/ETS Software |
Denys Osipenko |
source |
20 |
| SGF |
2016 |
Credit Risk Modeling in a New Era |
Wei Chen,
Martim Rocha,
Jimmy Skoglund |
source |
16 |
| PHUSE EU |
2015 |
A Simple and Novel Approach for the Assessment of Clinical Pharmacokinetics (Fast-track PK Analysis) [presentation] |
Ramanatha Saralaya,
Nand Kishore Rawat |
source |
12 |
| PHUSE EU |
2015 |
Programming Strategically for PK/PD Data |
Grace Lu |
source
presentation source |
8 |
| SESUG |
2015 |
Population Stability and Model Performance Metrics Replication for Business Model at SunTrust Bank |
Population Stability |
source |
6 |
| PharmaSUG |
2015 |
Growing Needs in Drug Industry for NONMEM Programmers Using SAS |
Sharmeen Reza |
source |
11 |
| PharmaSUG |
2015 |
Two different use cases to obtain best responses using RECIST 1.1: SDTM and ADaM |
Kevin Lee,
Vikash Jain |
source |
17 |
| SGF |
2015 |
Validation and Monitoring of PD Models for Low Default Portfolios Using PROC MCMC |
Machiel Kruger |
source |
16 |
| SCSUG |
2014 |
Building Better Credit Scores using Reject Inference and SAS |
Steve Fleming |
|
15 |
| PHUSE EU |
2014 |
Implementation of Oncology Specific SDTM Domains |
Jacintha Eben |
source
presentation source |
8 |
| PHUSE EU |
2014 |
NONMEM - A Programmers Point of View |
Raghu Kishor Koukuntla |
source
presentation source |
12 |
| PHUSE EU |
2014 |
Oncology Efficacy Endpoints |
Sarah Berenbrick |
source
presentation source |
3 |
| PharmaSUG |
2012 |
Streamlining Regulatory Submission with CDISC/ADaM Standards for Non-standard Pharmacokinetic/Pharmacodynamic Analysis Datasets |
Xiaopeng Li,
Katrina E. Canonizado,
Chun Feng,
Nancy Wang |
source |
6 |
| PharmaSUG |
2012 |
Tumor Assessment using RECIST: Behind the Scenes |
Suhas R. Sanjee,
Rajavel Ganesan,
Mary N. Varughese |
source |
7 |
| MWSUG |
2011 |
Using a Double DOW Loop to Compute Progression Free Survival |
Matthew Nizol |
|
9 |
| NESUG |
2011 |
Cash-Flow Modeling for Fixed Income Securities? A New Approach Using SAS Risk Management for Banking Solution |
Sunny Zhang |
|
14 |
| NESUG |
2011 |
Introduction to PK/PD Data Structures and Process Optimization to Get Analysis-Ready Data |
Smitha Mullapudi |
|
4 |
| SGF |
2011 |
Cash Flow Modeling for Fixed-Income Securities: A New Approach Using the SAS Risk Management for Banking Solution |
Sunny Zhang,
Jeff Hasmann,
Thomas Kimner |
source |
14 |
| SGF |
2011 |
Quantitative requirements for non-life insurance under Solvency 2 |
Sverre Grevskott |
source |
8 |
| SGF |
2009 |
A Comprehensive Credit Assessment Framework: Overview and Implications for the Subprime Crisis |
Clark R. Abrahams,
Sunny Zhang |
source |
14 |
| PHUSE EU |
2008 |
RECIST Temptation |
Paul Jenkins |
source |
8 |
| MWSUG |
2008 |
Creating Macros for Survival Data in Oncology Study |
Jagannath Ghosh |
|
8 |
| PharmaSUG |
2004 |
Automate Pharmacodynamic Analyses of Repeated Measure in Clinical Trials Using SAS Mixed Procedure |
Adeline Yeo,
Grace Li |
|
5 |
| NESUG |
2003 |
Using Cluster Analysis for Retail Portfolio Segmentation in an Economic Capital Model: Homogeneity by Common Default Behavior Over Time |
Shannon Kelly |
|
12 |
| SEUGI |
2003 |
Basel II and Beyond [presentation] |
Eva Wittmann,
Henrik Wagner,
Rik van de Weerthof,
Stefan de Lombaert |
source |
27 |
| NESUG |
2002 |
Integration of SAS and NONMEM for Automation of Population Pharmacokinetic/Pharmacodynamic Modeling on UNIX systems |
Alan Xiao,
Jill Fiedler-Kelly |
|
5 |
| SEUGI |
2000 |
Credit Risk Measurement for a Bank Loans Portfolio |
Emiliano Laruccia,
Valter Lazzari |
source |
11 |
HOME
QUICK SEARCH
AUTHORS
KEYWORDS
HELP
BUGS